Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting [PDF]
Journal of Hematology and OncologyMenin inhibitors, which target the KMT2A-menin protein-protein interaction to inhibit blasts proliferation and induce differentiation, have demonstrated potential effects on acute leukemia subtypes characterized by overexpression of HOXA gene cluster and
Gejia Cao +3 more
exaly +3 more sources
Targeting the undruggable: menin inhibitors ante portas [PDF]
Journal of Cancer Research and Clinical Oncology, 2023 Acute myeloid leukaemias harbouring a rearrangement of the mixed lineage leukaemia gene (MLL) are aggressive haematopoietic malignancies that relapse early and have a poor prognosis (event-free survival less than 50%). Menin is a tumour suppressor, however, in MLL-rearranged leukaemias it functions as a co-factor which is mandatory for the leukaemic ...
Patrizia Chiusolo +2 more
exaly +4 more sources
A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia [PDF]
Hematology ReportsMenin inhibitors are new and promising agents currently in clinical development that target the HOX/MEIS1 transcriptional program which is critical for leukemogenesis in histone-lysine N-methyltransferase 2A-rearranged (KMT2Ar) and in NPM1-mutated ...
Anna Candoni, Anna Candoni
exaly +4 more sources
Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation [PDF]
Oncology and TherapyRecent advances have included insights into the clinical value of genomic abnormalities in acute myeloid leukemia (AML) and consequently the development of numerous targeted therapeutic agents that have improved clinical outcome. In this setting, various
Xavier Thomas
exaly +3 more sources
Menin-MLL inhibitors as a new therapeutic target for middle ear cholesteatoma [PDF]
Scientific ReportsMiddle ear cholesteatoma (cholesteatoma), also known as a cholesteatomatous chronic otitis media, is concerning because it expands into the middle ear with bone destruction and causes irreversible hearing loss.
Naotaro Akiyama, Hiromi Kojima
exaly +3 more sources
Menin and BCL2 inhibitors– shaken and stirred [PDF]
HaematologicaNot available.
Alex Bataller, Ghayas C. Issa
doaj +4 more sources
CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trials [PDF]
Nature CommunicationsMenin inhibitors have entered clinical trials for histone lysine methyltransferase 2 A (KMT2A)-rearranged and nucleophosmin 1 (NPM1)-mutant acute leukemias and are demonstrating promising activity.
Wallace Bourgeois +22 more
doaj +2 more sources
Molecules, 2023 Encoded by the MEN1 gene, menin protein is a fusion protein that is essential for the oncogenic transformation of mixed-lineage leukemia (MLL) and leads to acute leukemia (AL). Therefore, accumulating evidence has demonstrated that inhibition of the high-
Yakun Luo, Meiqi Xu
exaly +3 more sources
Clinical research progress of menin inhibitors for acute myeloid leukemia: latest updates from the 2025 ASH Annual Meeting [PDF]
Experimental Hematology & OncologyMenin inhibition has emerged as a promising therapeutic strategy for acute myeloid leukemia (AML) driven by KMT2A rearrangements or NPM1 mutations. Novel menin inhibitors, including revumenib, bleximenib, ziftomenib, and enzomenib, are currently under ...
Chenchen Ma, Siyuan Cui, Jingyi Wang
doaj +2 more sources
Menin inhibitors for acute myeloid leukemia: latest updates from the 2023 ASH Annual Meeting [PDF]
Journal of Hematology & OncologyRecent developments in menin inhibitors for relapsed or refractory acute myeloid leukemia (AML) were highlighted at the 2023 ASH Annual Meeting. Notably, revumenib showed promising efficacy, achieving a 100% ORR when combined with decitabine/cedazuridine
Zhuo-Yu An, Xiao-Hui Zhang
doaj +2 more sources